Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer

MicroRNAs (miRNAs) are short, non-coding RNA molecules that act as regulators of gene expression. Circulating blood miRNAs have potential as cancer biomarkers. The main objective of the present study was to assess the effect of miRNA-23b (miR-23b) expression in plasma on the diagnosis and prognosis...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2016-12, Vol.12 (6), p.4838-4844
Main Authors: Kou, Chang-Hua, Zhou, Tian, Han, Xi-Lin, Zhuang, Hui-Jie, Qian, Hai-Xin
Format: Article
Language:English
Subjects:
Biomarkers
Bladder cancer
Blood plasma
Care and treatment
Colonoscopy
Colorectal cancer
Development and progression
diagnosis
Females
Gender
Gene expression
Genetic aspects
Health aspects
Hospitals
Lymphatic system
Medical diagnosis
Medical prognosis
Metastasis
methylation
MicroRNA
MicroRNAs
miR-23b
Multivariate analysis
Oncology
Patients
plasma
Prognosis
Prostate cancer
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MicroRNAs (miRNAs) are short, non-coding RNA molecules that act as regulators of gene expression. Circulating blood miRNAs have potential as cancer biomarkers. The main objective of the present study was to assess the effect of miRNA-23b (miR-23b) expression in plasma on the diagnosis and prognosis of colorectal cancer (CRC). Reverse transcription-quantitative polymerase chain reaction (PCR) was used to measure miR-23b expression levels, and methylation-specific PCR was used to test the promoter methylation status. Subsequently, the expression level of miR-23b in plasma samples was compared between CRC patients and healthy control individuals. The miR-23b expression levels were significantly lower in CRC cells and primary CRC tissues than in nonmalignant colorectal tissues (P
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2016.5265